nach oben

Archives of Virology

Erschienen in:

01.05.2024 | Original Article

miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2

verfasst von: Shijie Wang, Ying Xie, Fufei Liu, Jianrong Wang, Yinghao Yang, Junxue Wang, Yongxiang Wang, Xiaofeng Hang

Erschienen in: Archives of Virology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Transcription of the covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is subject to dual regulation by host factors and viral proteins. MicroRNAs (miRNAs) can regulate the expression of target genes at the post-transcriptional level. Systematic investigation of miRNA expression in HBV infection and the interaction between HBV and miRNAs may deepen our understanding of the transcription mechanisms of HBV cccDNA, thereby providing opportunities for intervention. miRNA sequencing and real-time quantitative PCR (qRT-PCR) were used to analyze miRNA expression after HBV infection of cultured cells. Clinical samples were analyzed for miRNAs and HBV transcription-related indicators, using qRT-PCR, enzyme-linked immunoassay (ELISA), and Western blot. miRNA mimics or inhibitors were used to study their effects on the HBV life cycle. The target genes of miR-3188 and their roles in HBV cccDNA transcription were also identified. The expression of 10 miRNAs, including miR-3188, which was significantly decreased after HBV infection, was measured in clinical samples from patients with chronic HBV infection. Overexpression of miR-3188 inhibited HBV transcription, whereas inhibition of miR-3188 expression promoted HBV transcription. Further investigation confirmed that miR-3188 inhibited HBV transcription by targeting Bcl-2. miR-3188 is a key miRNA that regulates HBV transcription by targeting the host protein Bcl-2. This observation provides insights into the regulation of cccDNA transcription and suggests new targets for anti-HBV treatment.

Nur mit Berechtigung zugänglich

Jeng WJ, Papatheodoridis GV, Lok ASF (2023) Hepatitis B. Lancet 401:1039–1052. https://doi.org/10.1016/s0140-6736(22)01468-4CrossRefPubMed

Xia Y, Guo H (2020) Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res 180:104824. https://doi.org/10.1016/j.antiviral.2020.104824CrossRefPubMedPubMedCentral

Li Q, Sun B, Zhuo Y, Jiang Z, Li R, Lin C, Jin Y, Gao Y, Wang D (2022) Interferon and interferon-stimulated genes in HBV treatment. Front Immunol 13:1034968. https://doi.org/10.3389/fimmu.2022.1034968CrossRefPubMedPubMedCentral

Shang R, Lee S, Senavirathne G, Lai EC (2023) microRNAs in action: biogenesis, function and regulation. Nat Rev Genet 24:816–833. https://doi.org/10.1038/s41576-023-00611-yCrossRefPubMed

Meng Q, Sun H, Wu S, Familiari G, Relucenti M, Aschner M, Li X, Chen R (2022) Epstein-Barr Virus-Encoded MicroRNA-BART18-3p Promotes Colorectal Cancer Progression by Targeting De Novo Lipogenesis. Adv Sci (Weinh) 9:e2202116. https://doi.org/10.1002/advs.202202116CrossRefPubMed

Zhang MH, Yuan YF, Liu LJ, Wei YX, Yin WY, Zheng LZ, Tang YY, Lv Z, Zhu F (2023) Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 29:4706–4735. https://doi.org/10.3748/wjg.v29.i31.4706CrossRefPubMedPubMedCentral

Ergün S, Sankaranarayanan R, Petrović N (2023) Clinically informative microRNAs for SARS-CoV-2 infection. Epigenomics 15:705–716. https://doi.org/10.2217/epi-2023-0179CrossRefPubMed

Dass D, Dhotre K, Chakraborty M, Nath A, Banerjee A, Bagchi P, Mukherjee A (2023) (2). Viruses 15:429. https://doi.org/10.3390/v15020429CrossRefPubMedPubMedCentral

Zhao X, Sun L, Mu T, Yi J, Ma C, Xie H, Liu M, Tang H (2020) An HBV-encoded miRNA activates innate immunity to restrict HBV replication. J Mol Cell Biol 12:263–276. https://doi.org/10.1093/jmcb/mjz104CrossRefPubMed

10.

Li F, Deng Y, Zhang S, Zhu B, Wang J, Wang J, Wang X, Zhao Z, Deng W, Mao R, Shen Z, Chen J, Broering R, Lin Y, Lu M, Zhang J (2022) Human hepatocyte-enriched miRNA-192-3p promotes HBV replication through inhibiting Akt/mTOR signalling by targeting ZNF143 in hepatic cell lines. Emerg Microbes Infect 11:616–628. https://doi.org/10.1080/22221751.2022.2037393CrossRefPubMedPubMedCentral

11.

Loukachov V, van Dort KA, Jansen L, Reesink HW, Kootstra NA (2022) Identification of a Novel HBV Encoded miRNA Using Next Generation Sequencing. Viruses 14:1223. https://doi.org/10.3390/v14061223CrossRefPubMedPubMedCentral

12.

Zhang Z, Chen J, He Y, Zhan X, Zhao R, Huang Y, Xu H, Zhu Z, Liu Q (2014) miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene. Arch Virol 159:3335–3343. https://doi.org/10.1007/s00705-014-2208-yCrossRefPubMed

13.

Li C, Wang Y, Liu T, Niklasch M, Qiao K, Durand S, Chen L, Liang M, Baumert TF, Tong S, Nassal M, Wen YM, Wang YX (2019) An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. Antiviral Res 162:118–129. https://doi.org/10.1016/j.antiviral.2018.12.019CrossRefPubMed

14.

Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM (2020) Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol 72:865–876. https://doi.org/10.1016/j.jhep.2019.12.009CrossRefPubMed

15.

Wang Y, Yuan W, Guo S, Li Q, Chen X, Li C, Liu Q, Sun L, Chen Z, Yuan Z, Luo C, Chen S, Tong S, Nassal M, Wen YM, Wang YX (2022) A 33-residue peptide tag increases solubility and stability of Escherichia coli produced single-chain antibody fragments. Nat Commun 13:4614. https://doi.org/10.1038/s41467-022-32423-9CrossRefPubMedPubMedCentral

16.

Wang X, Qin X, Yan M, Shi J, Xu Q, Li Z, Yang W, Zhang J, Chen W (2019) Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression. J Experimental Clin Cancer Res 38:151. https://doi.org/10.1186/s13046-019-1144-9CrossRef

17.

Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH (2019) An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol 234:5451–5465. https://doi.org/10.1002/jcp.27486CrossRefPubMed

18.

Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, Chen L, Chen Y, Duan Z, Meng S (2010) miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 398:771–777. https://doi.org/10.1016/j.bbrc.2010.07.021CrossRefPubMed

19.

Wu W, Wu D, Yan W, Wang Y, You J, Wan X, Xi D, Luo X, Han M, Ning Q (2021) Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. J Infect Dis 223:686–698. https://doi.org/10.1093/infdis/jiaa399CrossRefPubMed

20.

Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K, Jacob ST (2008) Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68:5049–5058. https://doi.org/10.1158/0008-5472.Can-07-6655CrossRefPubMedPubMedCentral

21.

Chen X, Chen J (2018) miR-3188 Regulates Cell Proliferation, Apoptosis, and Migration in Breast Cancer by Targeting TUSC5 and Regulating the p38 MAPK Signaling Pathway. Oncol Res Featuring Preclinical Clin Cancer Ther 26:363–372. https://doi.org/10.3727/096504017x14953948675421CrossRef

22.

Januszyk P, Januszyk K, Wierzbik-Strońska M, Boroń D, Grabarek B (2021) Analysis of the Differences in the Expression of mRNAs and miRNAs Associated with Drug Resistance in Endometrial Cancer Cells Treated with Salinomycin. Curr Pharm Biotechnol 22:541–548. https://doi.org/10.2174/1389201021666200629151008CrossRefPubMed

23.

Wang C, Liu E, Li W, Cui J, Li T (2018) MiR-3188 Inhibits Non-small Cell Lung Cancer Cell Proliferation Through FOXO1-Mediated mTOR-p-PI3K/AKT-c-JUN Signaling Pathway. Front Pharmacol 9:1362. https://doi.org/10.3389/fphar.2018.01362CrossRefPubMedPubMedCentral

24.

Hong SE, Jin HO, Kim SM, Jang SK, Park CS, Seong MK, Kim HA, Noh WC, Park IC (2021) miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor. Anticancer Res 41:6169–6176. https://doi.org/10.21873/anticanres.15436CrossRefPubMed

25.

Xu J, Liu F, Xia Z, He K, Xiang G (2021) MiR-3188 regulates the proliferation and apoptosis of hepatocellular carcinoma cells by targeting CXCL14. Biomark Med 15:1611–1621. https://doi.org/10.2217/bmm-2020-0685CrossRefPubMed

26.

Zhou S-j, Deng Y-l, Liang H-f, Jaoude JC, Liu F-y (2017) Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. Cell Death Differ 24:1577–1587. https://doi.org/10.1038/cdd.2017.87CrossRefPubMedPubMedCentral

27.

Korsmeyer SJ (1999) BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59:1693s–1700sPubMed

28.

Seo W, Gao Y, He Y, Sun J, Xu H, Feng D, Park SH, Cho YE, Guillot A, Ren T, Wu R, Wang J, Kim SJ, Hwang S, Liangpunsakul S, Yang Y, Niu J, Gao B (2019) ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J Hepatol 71:1000–1011. https://doi.org/10.1016/j.jhep.2019.06.018CrossRefPubMedPubMedCentral

29.

Wang C, Yao B, Xu M, Zheng X (2016) RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. Tumour Biol 37:15305–15313. https://doi.org/10.1007/s13277-016-5342-1CrossRefPubMed

30.

Zhang J, Liu Z, Liu L, Huang M, Huang Y (2022) Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3. Cytotechnology 74:203–216. https://doi.org/10.1007/s10616-021-00517-9CrossRefPubMedPubMedCentral

31.

Chang CS, Huang SM, Lin HH, Wu CC, Wang CJ (2007) Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma. Hepatogastroenterology 54:2061–2068PubMed

32.

Schuch A, Salimi Alizei E, Heim K, Wieland D, Kiraithe MM, Kemming J, Llewellyn-Lacey S, Sogukpinar Ö, Ni Y, Urban S, Zimmermann P, Nassal M, Emmerich F, Price DA, Bengsch B, Luxenburger H, Neumann-Haefelin C, Hofmann M, Thimme R (2019) Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8 + T cells in chronically HBV-infected patients with low viral load. Gut 68:905–915. https://doi.org/10.1136/gutjnl-2018-316641CrossRefPubMed

33.

Zhang TY, Chen HY, Cao JL, Xiong HL, Mo XB, Li TL, Kang XZ, Zhao JH, Yin B, Zhao X, Huang CH, Yuan Q, Xue D, Xia NS, Yuan YA (2019) Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nat Commun 10:3192. https://doi.org/10.1038/s41467-019-11173-1CrossRefPubMedPubMedCentral

34.

Geng X, Huang C, Qin Y, McCombs JE, Yuan Q, Harry BL, Palmer AE, Xia N-S, Xue D (2012) Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proceedings of the National Academy of Sciences 109:18471–18476. https://doi.org/10.1073/pnas.1204668109

Titel: miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2
verfasst von: Shijie Wang
Ying Xie
Fufei Liu
Jianrong Wang
Yinghao Yang
Junxue Wang
Yongxiang Wang
Xiaofeng Hang
Publikationsdatum: 01.05.2024
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 5/2024
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-024-05992-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Phylodynamic analysis of foot-and-mouth disease virus evolution in Mar Chiquita, Argentina

In vitro suppression of porcine epidemic diarrhea virus by Panax notoginseng saponins: assessing antiviral potential

Correction: Comparison between different conditions for the incorporation of foreign proteins into Autographa californica multiple nucleopolyhedrovirus polyhedra for biotechnological purposes

Prevalence, genotypes, and infection risk factors of psittacine beak and feather disease virus and budgerigar fledgling disease virus in captive birds in Hong Kong

Development of a novel sensitive single-tube nested PCR assay for the detection of African swine fever virus